<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624517</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00027015</org_study_id>
    <nct_id>NCT03624517</nct_id>
  </id_info>
  <brief_title>Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices</brief_title>
  <acronym>LOVARB</acronym>
  <official_title>Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of 24-hour vs 72-hour octreotide infusion after
      variceal banding in cirrhotic patients with bleeding esophageal varices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In cirrhotic patients with bleeding esophageal varices, standard of care therapy includes
      administration of octreotide infusion over 72-hours and endoscopic banding of esophageal
      varices.

      Octreotide acts to reduce the pressure in the blood vessels surrounding the liver, decreasing
      the propensity of bleeding from esophageal varices. The recommended duration of octreotide
      therapy is based largely on expert opinion, however a 72-hour duration of treatment is likely
      to be unnecessary and may inappropriately increase hospital and medical costs.

      This study aims to determine the safety of 24-hours of octreotide infusion in patients with
      bleeding esophageal varices.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Esophageal varices rebleed within 72-hours after control of initial bleed</measure>
    <time_frame>72 hours</time_frame>
    <description>Rebleeding within 72-hours will be defined as any of the following:
A drop in hemoglobin by more than 20 percentage points from baseline
Sustained tachycardia above 100 beats per minute, with or without hematochezia or melena
Transfusion of &gt;2 unites packed red blood cells after esophageal band ligation
Recurrence of hematemesis or ongoing melena
Urgent or emergent need for Transjugular Intrahepatic Portosystemic Shunt (TIPS) to control suspected rebleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Esophageal varices rebleed at 7 days and 30 days after control of initial bleed</measure>
    <time_frame>7 days and 30 days</time_frame>
    <description>Rebleeding after 72-hours will be defined as:
Any new episode of hematemesis, melena, or hematochezia (with hemodynamic instability)
Drop in hemoglobin by more than 20 percentage points OR the need for &gt;2 units packed red blood cells
Need for TIPS or surgery to control suspected bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 7 days and 30 days after control of initial bleed</measure>
    <time_frame>7 days and 30 days</time_frame>
    <description>Survival at 7 days and 30 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Esophageal Varices</condition>
  <condition>Liver Cirrhoses</condition>
  <condition>Bleeding Esophageal Varices</condition>
  <condition>Upper Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>24-hour octreotide infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive octreotide infusion over 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>72-hour octreotide infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive octreotide infusion over 72 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Octreotide infusion for 24-hours in patients with bleeding esophageal varices.</description>
    <arm_group_label>24-hour octreotide infusion</arm_group_label>
    <arm_group_label>72-hour octreotide infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males and females who are 18 years of age or older.

          2. Evidence or suspicion of upper gastrointestinal bleed (GIB)

          3. Patient with known or suspected cirrhosis

          4. Upper GIB secondary to bleeding esophageal varices as show by esophageal endoscopy,
             requiring endoscopic band ligation (EBL) at presentation

          5. Willing and able to provide informed consent for study, or have a Legally authorized
             representative (LAR) provide consent if the patient is unable to do so

        Exclusion Criteria:

          1. Known upper gastrointestinal malignancy

          2. Bleeding from gastric varices, with or without esophageal varices

          3. Use of any other endoscopic method to stop GI bleeding beyond endoscopic band ligation

          4. Variceal bleeding in the last 90 days

          5. History of transjugular, intrahepatic, portosystemic shunt (TIPS) or vascular
             decompression surgery

          6. Pregnant females

          7. Incarcerated individuals

          8. Myocardial infarct, cerebrovascular accident, sepsis, respiratory failure, or severe
             intercurrent illness within the previous 6 weeks

          9. Non-cirrhotic portal hypertension causing esophageal varices

         10. Known or suspected allergy to octreotide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Rockey, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali Khalifa, M.D</last_name>
    <phone>843-345-7071</phone>
    <email>khalifa@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mona Haj, M.D</last_name>
    <phone>843-729-8152</phone>
    <email>hajm@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Malespin, M.D</last_name>
      <email>miguel.malespin@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asim Shuja, MD</last_name>
      <email>ashuja@uic.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio state University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Lara, M.D</last_name>
      <phone>614-293-8000</phone>
      <email>Luis.Lara@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvio De Melo</last_name>
      <email>demelo@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Rockey, M.D</last_name>
      <phone>843-792-2914</phone>
      <email>rockey@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Roula Sasso, M.D</last_name>
      <email>sasso@musc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Texas at Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda A Feagins, MD</last_name>
      <email>linda.feagins@austin.utexas.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deepak Agrawal, MD</last_name>
      <phone>5124955618</phone>
      <email>deepak.agrawal@austin.utexas.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Mendoza-Ladd, MD</last_name>
      <email>Antonio.Mendoza-Ladd@ttuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Casner</last_name>
      <email>Nancy.Casner@ttuhsc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Edelson, MD</last_name>
      <email>jerry.edelson@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

